Skip to main content

Advertisement

Log in

Anti-leishmanial compounds from microbial metabolites: a promising source

  • Mini-Review
  • Published:
Applied Microbiology and Biotechnology Aims and scope Submit manuscript

Abstract

Leishmania is a complex disease caused by the protozoan parasites and transmitted by female phlebotomine sandfly. The disease affects some of the poorest people on earth with an estimated 700,000 to 1 million new cases annually. The current treatment for leishmaniasis is toxic, long, and limited, in view of the high resistance rate presented by the parasite, necessitating new perspectives for treatment. The discovery of new compounds with different targets can be a hope to make the treatment more efficient. Microbial metabolites and their structural analogues with enormous scaffold diversity and structural complexity have historically played a key role in drug discovery. We found thirty-nine research articles published between 1999 and 2021 in the scientific database (PubMed, Science Direct) describing microbes and their metabolites with activity against leishmanial parasites which is the focus of this review.

Key points

Leishmania affects the poorest regions of the globe

Current treatments for leishmaniasis are toxic and of limited efficacy

Microbial metabolites are potential sources of antileishmania drugs

Graphical abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

Download references

Acknowledgements

We would like to thank CAPES (Coordenação Aperfeiçoamento de Pessoal de Nivel Superior) for the master scholarship that supported the first author. We would also like to thank Camilla Valenca for the support provided in structuring Figure 1. Eliana B. Souto is thankful to the Portuguese Foundation for Science and Technology (FCT/MEC) for the project UIDB/04469/2020 granted through national funds, and co-financed by FEDER, under the Partnership Agreement PT2020.

Author information

Authors and Affiliations

Authors

Contributions

AFSC, YLDCO, SSD and RS contributed for the conceptualization, methodology, validation, formal analysis, and investigation, and writing—original draft preparation. EBS, JAL and SJ contributed for the methodology, supervision, writing—review and editing, project administration, resources, and funding acquisition. All authors have made a substantial contribution to the work. All authors have read and agreed to the published version of the manuscript.

Corresponding authors

Correspondence to Eliana B. Souto or Sona Jain.

Ethics declarations

Ethics approval

The manuscript is in compliance with Ethical Standards.

No ethics issues are raised in this manuscript

This article does not contain any studies with human participants or animals performed by any of the authors.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

da Cunha, A.F.S., Di C. Oliveira, Y.L., Dolabella, S.S. et al. Anti-leishmanial compounds from microbial metabolites: a promising source. Appl Microbiol Biotechnol 105, 8227–8240 (2021). https://doi.org/10.1007/s00253-021-11610-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00253-021-11610-6

Keywords

Navigation